- Home
- MGY vs DNLI Comparison
MGY vs DNLI Comparison
Compare MGY & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGY
- DNLI
- Stock Information
- Founded
- MGY 2017
- DNLI 2013
- Country
- MGY United States
- DNLI United States
- Employees
- MGY N/A
- DNLI N/A
- Industry
- MGY Oil & Gas Production
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGY Energy
- DNLI Health Care
- Exchange
- MGY Nasdaq
- DNLI Nasdaq
- Market Cap
- MGY 5.2B
- DNLI 4.5B
- IPO Year
- MGY 2017
- DNLI 2017
- Fundamental
- Price
- MGY $27.70
- DNLI $24.42
- Analyst Decision
- MGY Buy
- DNLI Strong Buy
- Analyst Count
- MGY 13
- DNLI 11
- Target Price
- MGY $26.45
- DNLI $38.90
- AVG Volume (30 Days)
- MGY 1.5M
- DNLI 854.8K
- Earning Date
- MGY 10-30-2024
- DNLI 11-06-2024
- Dividend Yield
- MGY 1.89%
- DNLI N/A
- EPS Growth
- MGY N/A
- DNLI N/A
- EPS
- MGY 2.02
- DNLI N/A
- Revenue
- MGY $1,311,905,000.00
- DNLI N/A
- Revenue This Year
- MGY $8.48
- DNLI N/A
- Revenue Next Year
- MGY $0.53
- DNLI $283.75
- P/E Ratio
- MGY $13.64
- DNLI N/A
- Revenue Growth
- MGY 4.67
- DNLI 204.74
- 52 Week Low
- MGY $19.16
- DNLI $14.56
- 52 Week High
- MGY $27.96
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- MGY 61.42
- DNLI 36.71
- Support Level
- MGY $27.10
- DNLI $23.53
- Resistance Level
- MGY $27.70
- DNLI $33.33
- Average True Range (ATR)
- MGY 0.68
- DNLI 1.68
- MACD
- MGY 0.08
- DNLI -0.58
- Stochastic Oscillator
- MGY 91.28
- DNLI 9.08
About MGY Magnolia Oil & Gas Corporation
Magnolia Oil & Gas Corp is an independent oil and natural gas company engaged in the acquisition, development, exploration, and production of oil, natural gas, and natural gas liquid (NGL) reserves. The Company's oil and natural gas properties are located in Karnes County and the Giddings area in South Texas, where the Company targets the Eagle Ford Shale and Austin Chalk formations. Its objective is to generate stock market value over the long term through consistent organic production growth, high full-cycle operating margins, and an efficient capital program with short economic paybacks. The company's operating segment is acquisition, development, exploration, and production of oil and natural gas properties located in the United States.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.